To identify potential active ingredients in SM injection for IPF treatment, we conducted molecular docking on the 16 components, using the 3 core therapeutic targets (MMP9, IL-6, and TNF-α) as receptors. The gene discussed is TNF; the disease is idiopathic pulmonary fibrosis.